Answers are grounded in this paper and cite their sources.
Daily fezolinetant 30 and 45 mg were efficacious and well tolerated for treating moderate to severe VMS associated with menopause.
No takes yet. Share an insight, caveat, or question.
Johnson et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: